Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study

• Status: Terminated
• Trial end date: 2017-12-01

Summary

The purpose of this study is to select targeted treatment based on ex vivo kinase activity inhibition profiles to targeted agents of tumor tissue from patients with advanced cancer for whom no standard treatment is available.

• Phase: N/A

Details

• Lead Sponsor: VU University Medical Center
• Collaborator: VitrOmics BV
• Treatments: Erlotinib Hydrochloride; Everolimus; Lapatinib; Sirolimus; Sorafenib; Sunitinib